Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.69 |
| ▸ | MMP13 | P45452 | 18/20 | 0.69 |
| ▸ | ADAM17 | P78536 | 16/20 | 0.69 |
| ▸ | MMP9 | P14780 | 7/20 | 0.66 |
| ▸ | MMP2 | P08253 | 7/20 | 0.66 |
| ▸ | MMP3 | P08254 | 7/20 | 0.66 |
| ▸ | MMP7 | P09237 | 4/20 | 0.66 |
| ▸ | MMP8 | P22894 | 3/20 | 0.66 |
| ▸ | MMP14 | P50281 | 2/20 | 0.66 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.65 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27523269 | 0.90 | MMP1 (0.54) | MMP1MMP13ADAM17MMP9MMP2 | |
| SCHEMBL6381644 | 0.88 | MMP1 (0.69) | MMP1MMP13ADAM17MMP9MMP2 | |
| SCHEMBL6386785 | 0.86 | MMP1 (0.53) | MMP1MMP13ADAM17MMP2MMP3 | |
| SCHEMBL5758644 | 0.85 | MMP1 (0.73) | MMP1ADAM17 | |
| SCHEMBL6381652 | 0.85 | MMP1 (0.78) | MMP1MMP13ADAM17MMP9MMP2 | |
| SCHEMBL7765024 | 0.85 | MMP1 (0.78) | MMP1MMP13ADAM17MMP9MMP2 | |
| SCHEMBL7055124 | 0.82 | MMP1 (0.73) | MMP1MMP13ADAM17MMP9MMP2 | |
| SCHEMBL7055128 | 0.82 | MMP1 (0.73) | MMP1MMP13ADAM17MMP9MMP2 | |
| SCHEMBL7051190 | 0.82 | MMP1 (0.70) | MMP1MMP13ADAM17MMP9MMP2 | |
| SCHEMBL7051193 | 0.82 | MMP1 (0.70) | MMP1MMP13ADAM17MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215549-A1 | TACE inhibitors | MCCLURE KIM F | 2005-09-29 | — | — | US | disclosed |
| US-20030181441-A1 | TACE INHIBITORS | McCLURE Kim (US) | 2003-09-25 | — | — | US | disclosed |
| EP-0960098-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998034918-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181441-A1 | TACE INHIBITORS | ADAMTS5, ADAMTS1, MMP2 | MMP1 18/4885MMP13 35/4885ADAM17 22/4885 |
| US-20050215549-A1 | TACE inhibitors | ADAMTS5, ADAMTS1, MMP2 | MMP1 15/4885MMP13 34/4885ADAM17 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.